Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View

Key Takeaways Insmed posted a wider Q4 loss of $1.54 per share as revenues jumped 153% to $263.8M.Brinsupri delivered $144.6M in Q4 sales; 2026 guidance calls for at least $1B.Arikayce sales rose 14% to $119.2M; R&D and SG&A expenses climbed sharply.Insmed (INSM) reported a fourth-quarter 2025 loss of $1.54 per share, wider than the Zacks Consensus Estimate of a loss of $1.07. In the year-ago quarter, the company had incurred a loss of $1.32.Quarterly revenues rose 153% year over year to over $263.8 million ...